Twist Bioscience and Neogene Announce Broad Strategic Partnership for Next Generation Personalized T Cell Therapies
Partnership Combines Twist’s Leadership in DNA Synthesis and Synthetic Biology with Neogene’s Expertise in Personalized Engineered T Cell Therapies
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201013005372/en/
“Engineered T cell therapies have demonstrated benefit to patients with difficult-to-treat cancers. We are delighted to partner with Neogene, a company pioneering fully personalized T cell therapies for solid tumors,” said Emily M. Leproust, Ph.D., CEO and co-founder of
“Neogene is committed to changing the treatment paradigm for solid cancers using our novel technology to provide access to tumor-specific TCRs for engineered T cell therapy on an individualized patient basis. Twist’s proven ability to make synthetic DNA products at scale provides a tremendous engine to power innovative, precise cancer therapeutics,” said
Under the terms of the collaboration, Neogene and Twist will work together to develop novel tools for T cell therapies. Twist Biopharma, a division of
Twist will receive technology access fees as well as milestones and royalties based on key preclinical, clinical and commercial milestones for any antibodies and T cell receptors resulting from the collaboration. Neogene will have exclusive rights to the synthetic TCR library for targeting viral and neo-antigens in the field of oncology.
About Neogene Therapeutics
Neogene Therapeutics is a pre-clinical stage biotechnology company pioneering development of next-generation, fully personalized engineered T cells therapies for a broad spectrum of cancers. The Company’s engineered T cells target tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, that render tumor cells vulnerable to detection by T cells. Neogene’s proprietary technology platform aims to identify TCR genes with specificity for neo-antigens from a tumor biopsy. Since every cancer expresses a unique set of neo-antigens, Neogene’s novel approach delivers a tailored set of TCR genes for each individual patient. These TCR genes are engineered into patient-derived T cells directing them towards neo-antigens in tumor cells, thereby providing a fully personalized engineered T cell therapy for cancer. For more information, please visit www.neogene.com, and follow @Neogene Therapeutics on LinkedIn.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the ability of Twist’s partnership with Neogene to successfully develop personalized T cell treatments for cancer and expedite the development of revolutionary treatment options for solid cancers, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products
Twist Bioscience Investor Contact:
Twist Bioscience Media Contact:
Neogene Media Contact: